In our report, NEAT1 was found to act as an oncogene by activating the PI3K/AKT/mTOR pathway via modulating the miR-1294/AKT1 axis, providing novel evidence for NEAT1 as a diagnostic and therapeutic marker in the clinical treatment of GC. Here, AKT1 is linked to gastric cancer.